NASDAQ:LOGC - LogicBio Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $14.75
  • Forecasted Upside: 359.50 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$3.21
▼ -0.05 (-1.53%)

This chart shows the closing price for LOGC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New LogicBio Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for LOGC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for LOGC

Analyst Price Target is $14.75
▲ +359.50% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for LogicBio Therapeutics in the last 3 months. The average price target is $14.75, with a high forecast of $20.00 and a low forecast of $8.00. The average price target represents a 359.50% upside from the last price of $3.21.

This chart shows the closing price for LOGC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 contributing investment analysts is to buy stock in LogicBio Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/16/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/14/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/13/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/13/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/11/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/9/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/8/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/8/2021

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/17/2021BarclaysLower Price TargetOverweight$24.00 ➝ $8.00High
11/16/2021JMP SecuritiesLower Price TargetMarket Outperform$17.00 ➝ $16.00High
11/15/2021William BlairReiterated RatingOutperformHigh
9/27/2021JMP SecuritiesReiterated RatingBuy$17.00Low
7/7/2021Chardan CapitalReiterated RatingBuyLow
6/7/2021HC WainwrightInitiated CoverageBuy$15.00High
6/2/2021Chardan CapitalReiterated RatingBuy$20.00High
3/4/2021JMP SecuritiesInitiated CoverageOutperform$17.00High
3/1/2021William BlairReiterated RatingBuyLow
8/10/2020William BlairReiterated RatingBuyHigh
5/22/2020Chardan CapitalReiterated RatingBuy$20.00Low
5/12/2020Chardan CapitalReiterated RatingBuy$20.00High
5/12/2020William BlairReiterated RatingBuyMedium
3/17/2020Chardan CapitalReiterated RatingBuy$20.00High
3/17/2020William BlairReiterated RatingBuyHigh
1/10/2020William BlairReiterated RatingOutperformMedium
1/10/2020Chardan CapitalReiterated RatingBuy$20.00High
11/12/2019William BlairReiterated RatingBuyLow
8/15/2019Chardan CapitalReiterated RatingBuy$20.00Medium
7/29/2019Chardan CapitalReiterated RatingBuyMedium
5/1/2019Roth CapitalInitiated CoverageBuy ➝ Buy$26.00Medium
11/13/2018Chardan CapitalInitiated CoverageBuy ➝ Buy$20.00Low
11/13/2018BarclaysInitiated CoverageOverweight ➝ Overweight$24.00Low
11/13/2018William BlairInitiated CoverageOutperform ➝ Outperform$26.00Low
(Data available from 12/9/2016 forward)

News Sentiment Rating

-0.22 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/13/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/12/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/12/2021
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
8/11/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
9/10/2021
  • 0 very positive mentions
  • 1 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
10/10/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
11/9/2021
  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
12/9/2021

Current Sentiment

  • 0 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 1 very negative mentions
LogicBio Therapeutics logo
LogicBio Therapeutics, Inc. engages in the development of genome editing technology platform. It focuses on the commercialization of GeneRide, which enables the site-specific integration of a therapeutic transgene without nucleases or exogenous promoters by harnessing the native process of homologous recombination. Its pipeline include LB-001, LB-301, LB-201, and LB-101. The company was founded by Mark A. Kay, Leszek Lisowski, and Adi Barzel in August 2014 and is headquartered in Cambridge, MA.
Read More

Today's Range

Now: $3.21
Low: $3.15
High: $3.31

50 Day Range

MA: $3.67
Low: $2.83
High: $4.58

52 Week Range

Now: $3.21
Low: $2.75
High: $9.74

Volume

39,075 shs

Average Volume

129,600 shs

Market Capitalization

$105.79 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.05

Frequently Asked Questions

What sell-side analysts currently cover shares of LogicBio Therapeutics?

The following Wall Street research analysts have issued research reports on LogicBio Therapeutics in the last year: Barclays PLC, Chardan Capital, HC Wainwright, JMP Securities, William Blair, and Zacks Investment Research.
View the latest analyst ratings for LOGC.

What is the current price target for LogicBio Therapeutics?

4 Wall Street analysts have set twelve-month price targets for LogicBio Therapeutics in the last year. Their average twelve-month price target is $14.75, suggesting a possible upside of 359.5%. Chardan Capital has the highest price target set, predicting LOGC will reach $20.00 in the next twelve months. Barclays PLC has the lowest price target set, forecasting a price of $8.00 for LogicBio Therapeutics in the next year.
View the latest price targets for LOGC.

What is the current consensus analyst rating for LogicBio Therapeutics?

LogicBio Therapeutics currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe LOGC will outperform the market and that investors should add to their positions of LogicBio Therapeutics.
View the latest ratings for LOGC.

What other companies compete with LogicBio Therapeutics?

How do I contact LogicBio Therapeutics' investor relations team?

LogicBio Therapeutics' physical mailing address is 65 HAYDEN AVENUE 2ND FLOOR, LEXINGTON MA, 02421. The company's listed phone number is (617) 245-0399 and its investor relations email address is [email protected] The official website for LogicBio Therapeutics is www.logicbio.com.